Guidelines for Drug Donations - Revised 1999
(1999; 24 pages) [French] [Spanish] View the PDF document
Table of Contents
View the documentChanges incorporated into the 1999 edition
View the documentI. Introduction
View the documentII. The need for guidelines
View the documentIII. Core principles
Close this folderIV. Guidelines for drug donations
View the documentSelection of drugs
View the documentQuality assurance and shelf-life
View the documentPresentation, packing and labelling
View the documentInformation and management
Open this folder and view contentsV. Other ways donors can help
Open this folder and view contentsVI. How to implement a policy on drug donations
View the documentAnnex: Examples of problems with drug donations
View the documentAcknowledgements
View the documentReferences
View the documentBack Cover
 

Information and management

10. Recipients should be informed of all drug donations that are being considered, prepared or actually under way.

Justification and explanation

Many drug donations arrive unannounced. Detailed advance information on all drug donations is essential to enable the recipient to plan for the receipt of the donation and to coordinate the donation with other sources of supply. The information should at least include: the type and quantities of donated drugs including their International Nonproprietary Name (INN) or generic name, strength, dosage form, manufacturer and expiry date; reference to earlier correspondence (for example, the letter of consent by the recipient); the expected date of arrival and port of entry; and the identity and contact address of the donor.

11. In the recipient country the declared value of a drug donation should be based upon the wholesale price of its generic equivalent in the recipient country, or, if such information is not available, on the wholesale world-market price for its generic equivalent.

Justification and explanation

This provision is needed solely to prevent drug donations being valued in the recipient country according to the retail price of the product in the donor country. This may lead to elevated overhead costs for import tax, port clearance and handling in the recipient country. It may also result in a corresponding decrease in the public sector drug budget in the recipient country.

Possible exception

In the case of patented drugs (for which there is no generic equivalent) the wholesale price of the nearest therapeutic equivalent could be taken as a reference.

12. Costs of international and local transport, warehousing, port clearance and appropriate storage and handling should be paid by the donor agency, unless specifically agreed otherwise with the recipient in advance.

Justification and explanation

This provision prevents the recipient from being forced to spend effort and money on the clearance and transport of unannounced consignments of unwanted items, and also enables the recipient to review the list of donated items at an early stage.

to previous section to next section
 

Last updated: May 3, 2013